Table 1 Clinical, hematologic, bone marrow and immunophenotypic characteristics of 41 pure erythroid leukemia cases.
Variables | All patients |
|---|---|
N = 41 | |
Age at diagnosis in years; mean (range) | 68 (27–86) |
Male, n (%) | 29 (70.7%) |
Clinical presentation: | |
Primary, n (%) | 14 (34%) |
Therapy related, n (%) | 14 (34%) |
Secondary to MDS/MPN, n (%) | 12 (29) |
Unknown, n (%) | 1 (2%) |
Hemoglobin g/dL; mean (range) | 8.1 (5.9–11.3) |
Anemia, n (%) “N” evaluable = 40 | 40 (100%) |
Severe anemia, n (%) “N” evaluable = 40 | 19 (48%) |
Leukocytes x 109/L; mean (range) | 4.4 (0.6–23.9) |
ANC x 109/L; mean (range) | 1.9 (0–11.5) |
Neutropenia, n (%) “N” evaluable = 40 | 25 (63%) |
Degree of neutropenia: | |
Marked, n (%) | 10 (25%) |
Moderate, n (%) | 8 (20%) |
Mild, n (%) | 7 (18%) |
Platelets × 109/L; mean (range) | 32 (4–146) |
Thrombocytopenia, n (%) “N” evaluable = 40 | 39 (98%) |
Degree of thrombocytopenia: | |
Marked | 31 (78%) |
Moderate | 7 (18%) |
Mild | 1 (2%) |
Circulating blasts, n (%) “N” evaluable = 40 | 27 (68%) |
Circulating blast %; mean (range) | 11.5 (Rare-88) |
>80% bone marrow erythroid precursors, n (%) | 41 (100%) |
>30% bone marrow pronormoblasts, n (%) | 41 (100%) |
Dysplastic megakaryocytes, n (%) | 33 (80%) |
Ring sideroblasts, n (%) “N” evaluable = 31 | 22 (71%) |
Ring sideroblast %; mean (range) | 26 (Rare-80) |
Carcinoma-like pattern, n (%) | 8 (20%) |
Intrasinusoidal pattern, n (%) | 3 (7%) |
Immunophenotypic features by flow cytometry positive for; (%) | |
CD45 (“N” evaluable =28) | Weak positive (50%). |
CD34 (“N” evaluable =28) | Positive (25%); partial positive (18%). |
CD117 (“N” evaluable =28) | Positive (61%); partial positive (21%); weak positive (4%). |
CD36 (“N” evaluable =28) | Positive (96%). |
HLA-DR (“N” evaluable =28) | Positive (21%). |
CD13 (“N” evaluable =28) | Positive (43%); weak positive (4%); partial positive (21%). |
CD33 (“N” evaluable =28) | Positive (25%); partial positive (39%). |
CD7 (“N” evaluable =28) | Positive (36%); partial positive (39%). |
MPO (“N” evaluable =15) | Positive (0%). |
Immunophenotypic features by Immunohistochemistry positive for; (%) | |
CD34 (“N” evaluable =32) | Positive (16%); positive small subset (12%). |
CD117 (“N” evaluable =31) | Positive (68%); positive partial (19%); Weak (3%). |
CD71 (“N” evaluable =28) | Positive (96%); positive partial (4%). |
E-Cadherin (“N” evaluable =33) | Positive (88%); positive partial (6%). |
Hemoglobin (“N” evaluable =31) | Positive (0%); positive small subset (58%). |
Glycophorin A (“N” evaluable =12) | Positive (0%); positive small subset (33%). |
CD61 (“N” evaluable =32) | Positive (0%); positive small subset (9%). |
AE1/AE3 keratin (“N” evaluable =28) | Positive (0%) |
OSCAR (“N” evaluable =17) | Positive (0%) |
MPO (“N” evaluable =37) | Positive (0%) |
